Ind-Swift Labs.

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: INE915B01019
  • NSEID: INDSWFTLAB
  • BSEID: 532305
INR
386.10
8.6 (2.28%)
BSENSE

Sep 11, 03:30 PM

BSE+NSE Vol: 6.1 lacs

  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationScore
Part of MojoOne Strategy
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

Comparison

Company
Score
Quality
Valuation
Financial
Technical
Kwality Pharma
Sakar Healthcare
Aarti Drugs
Unichem Labs.
Solara Active
Ind-Swift Labs.
Hikal
SMS Pharma.
Advanced Enzyme
Dishman Carbogen
Zota Health Care

Why is Ind-Swift Laboratories Ltd ?

1
Weak Long Term Fundamental Strength with a -23.73% CAGR growth in Operating Profits over the last 5 years
  • The company has been able to generate a Return on Equity (avg) of 7.99% signifying low profitability per unit of shareholders funds
2
With a growth in Net Profit of 184.05%, the company declared Very Positive results in Jun 26
  • The company has declared positive results for the last 4 consecutive quarters
  • PBT LESS OI(Q) At Rs 25.15 cr has Grown at 694.56%
  • NET SALES(Latest six months) At Rs 361.24 cr has Grown at 24.15%
  • PAT(Latest six months) Higher at Rs 45.12 cr
3
With ROE of 3.6, it has a Very Expensive valuation with a 2.5 Price to Book Value
  • The stock is trading at a premium compared to its peers' average historical valuations
  • Over the past year, while the stock has generated a return of 258.10%, its profits have risen by 257.4% ; the PEG ratio of the company is 0.3
4
Falling Participation by Institutional Investors
  • Institutional investors have decreased their stake by -3.01% over the previous quarter and collectively hold 10.87% of the company
  • These investors have better capability and resources to analyse fundamentals of companies than most retail investors
stock-recommendationReal-Time Research Report

Verdict Report

How much should you hold?

  1. Overall Portfolio exposure to Ind-Swift Labs. should be less than 10%
  2. Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock

Is Ind-Swift Labs. for you?

High Risk, High Return

Absolute
Risk Adjusted
Volatility
Ind-Swift Labs.
258.1%
4.56
56.57%
Sensex
-8.3%
-0.62
13.46%
stock-recommendationQuality
stock-summaryManagement Risk
stock-summaryGrowth
stock-summaryCapital Structure
stock-recommendation
Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor
Value
Sales Growth (5y)
-6.51%
EBIT Growth (5y)
-23.73%
EBIT to Interest (avg)
7.43
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.31
Sales to Capital Employed (avg)
0.67
Tax Ratio
19.66%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
10.87%
ROCE (avg)
8.57%
ROE (avg)
7.99%
stock-recommendationValuation

Valuation Scorecard stock-summary

stock-recommendation
Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors stock-summary

Factor
Value
P/E Ratio
51
Industry P/E
37
Price to Book Value
2.45
EV to EBIT
105.60
EV to EBITDA
49.81
EV to Capital Employed
3.09
EV to Sales
4.47
PEG Ratio
0.34
Dividend Yield
NA
ROCE (Latest)
-0.08%
ROE (Latest)
3.61%
Loading Valuation Snapshot...
stock-recommendationTechnicals

Technical key factors

Indicator
Weekly
Monthly
MACD
Bullish
Bullish
RSI
Bearish
Bearish
Bollinger Bands
Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Bullish
Bullish
Dow Theory
Bullish
Bullish
OBV
Bullish
Bullish
stock-recommendation Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
Technical Movement
stock-recommendationFinancial Trend

Financial Trend Scorecard stock-summary

stock-recommendation
Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

28What is working for the Company
PBT LESS OI(Q)

At Rs 25.15 cr has Grown at 694.56%

NET SALES(Latest six months)

At Rs 361.24 cr has Grown at 24.15%

PAT(Latest six months)

Higher at Rs 45.12 cr

PBDIT(Q)

Highest at Rs 33.43 cr.

OPERATING PROFIT TO NET SALES(Q)

Highest at 17.46%

EPS(Q)

Highest at Rs 2.84

0What is not working for the Company
Icon
NO KEY NEGATIVE TRIGGERS
Loading Valuation Snapshot...

Here's what is working for Ind-Swift Labs.

Profit Before Tax less Other Income (PBT) - Quarterly
At Rs 25.15 cr has Grown at 694.56%
Year on Year (YoY)
MOJO Watch
Near term PBT trend is very positive

PBT less Other Income (Rs Cr)

Profit After Tax (PAT) - Quarterly
At Rs 24.86 cr has Grown at 183.5%
Year on Year (YoY)
MOJO Watch
Near term PAT trend is very positive

PAT (Rs Cr)

Net Sales - Quarterly
Highest at Rs 191.45 cr
in the last five quarters
MOJO Watch
Near term sales trend is positive

Net Sales (Rs Cr)

Net Sales - Quarterly
At Rs 191.45 cr has Grown at 25.35%
Year on Year (YoY)
MOJO Watch
Near term sales trend is positive

Net Sales (Rs Cr)

Operating Profit (PBDIT) - Quarterly
Highest at Rs 33.43 cr.
in the last five quarters
MOJO Watch
Near term Operating Profit trend is positive

Operating Profit (Rs Cr)

Operating Profit Margin - Quarterly
Highest at 17.46%
in the last five quarters
MOJO Watch
Company's efficiency has improved

Operating Profit to Sales

Profit Before Tax less Other Income (PBT) - Quarterly
Highest at Rs 25.15 cr.
in the last five quarters
MOJO Watch
Near term PBT trend is positive

PBT less Other Income (Rs Cr)

Profit After Tax (PAT) - Quarterly
Highest at Rs 24.86 cr.
in the last five quarters
MOJO Watch
Near term PAT trend is positive

PAT (Rs Cr)

Earnings per Share (EPS) - Quarterly
Highest at Rs 2.84
in the last five quarters
MOJO Watch
Increasing profitability; company has created higher earnings for shareholders

EPS (Rs)